Medico Intercontinental

Medico Intercontinental EBITDA per Share

The EBITDA per Share of Medico Intercontinental (539938.BO) as of Nov 17, 2026 is 8.78 INR. In the previous year, EBITDA per Share was 6.22 INR — a change of 41.12% (higher).

EBITDA per Share

8.78INR

YoY

41.12%

Last updated:

EBITDA per Share of Medico Intercontinental is 2025 8.78 INR. EBITDA per Share of Medico Intercontinental was 2024 6.22 INR. It decreases by 41.12% higher compared to the previous year.

The Medico Intercontinental EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2021
15.23 INR
Jan 1, 2022
16.34 INR
Jan 1, 2023
8.97 INR
Jan 1, 2024
6.22 INR
Jan 1, 2025
8.78 INR
The Medico Intercontinental EBITDA per Share history
YEAREBITDA per ShareYoY
8.78INR+41.12%
6.22INR-30.60%
8.97INR-45.13%
16.34INR+7.28%
15.23INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medico Intercontinental Stock analysis

What does Medico Intercontinental do? Medico Intercontinental Ltd. generates revenue through financing, trading, and investment in shares and securities. The company provides a platform for research-based biopharmaceutical companies, focusing on product categories such as gastro, uro, nutrition, cosmetology, health devices, and hospital services. Its product portfolio includes ACIFACT-BLI, ACIFACT-P, ACIFACT-SP (ALU-ALU), ALBECTIN, and other branded pharmaceuticals like CYCLOFACT 400, UDIFACT 150, and ZIFT SL - 250. Subsidiaries such as Evagrace Pharma Private Limited and Ritz Formulations Private Limited support its operations in the biopharmaceutical sector. The company serves biopharmaceutical firms seeking research-based solutions, with products distributed across gastroenterology, urology, nutrition, and cosmetology segments. Key brands like ALFACARE - D3, ARSUFACT Combokit, and BALOFACT target specific medical needs, while health devices and hospital-related products cater to broader healthcare markets. Subsidiaries like Sungrace Pharma Private Limited and Azillian Healthcare Private Limited contribute to the company's product development and market reach. Medico Intercontinental Ltd. monetizes its platform by facilitating trading and investment activities in securities, alongside its biopharmaceutical product sales. The company's subsidiaries manage production and distribution of branded pharmaceuticals, ensuring market presence in key healthcare segments. Products such as RELIEVE CZ, VOLIREX SPRAY, and ZYMIX SY are sold to healthcare providers and consumers in the biopharmaceutical industry. Medico Intercontinental is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medico Intercontinental stock

EBITDA per Share of Medico Intercontinental is 8.78 INR in 2025.

EBITDA per Share of Medico Intercontinental changed from 6.22 INR to 8.78 INR, representing a 41.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Medico Intercontinental since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Medico Intercontinental

All Key Metrics — Medico Intercontinental